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Introduction
Since 2004, the HIV Vaccines and Microbicides Resource
Tracking Working Group has employed a comprehensive
methodology to track resource trends in R&D for biome-
dical HIV prevention options, including HIV vaccines,
microbicides, PrEP, treatment as prevention, vertical trans-
mission prevention and adult voluntary medical male
circumcision.
Materials and methods
Data were collected on annual disbursements by public,
private and philanthropic funders for product develop-
ment, clinical trials and trial preparation, community edu-
cation and policy advocacy efforts in order to estimate
annual investment in HIV prevention R&D. Investment
trends were assessed and compared by year, prevention
technology type, type of funder and geographic location.
Results
Since 2000, there has been significant growth in funding
support for HIV prevention research and development.
However, in 2011 HIV prevention research began to face
increased funding pressures as governments worldwide
decreased or flat-lined budgets in many areas of global
health and as philanthropic donors worked to revise their
investment strategies. Competing funding priorities
affected funding for HIV prevention R&D. Still, despite
those various funding pressures, the field of HIV preven-
tion research progressed significantly in 2011, with new
findings that advanced the field and promising new trials
underway.
Conclusions
Monitoring funding trends for HIV prevention research
is particularly important at this time of critical juncture
between economic uncertainty and the point at which
the scientific community has articulated a much clearer
pathway to the end of the HIV epidemic. Monitoring
funding provides the fact base for policy advocacy around
spending levels and allocations that will sustain invest-
ments in the research required to build on the success of
recent trials; bring novel HIV prevention candidates into
the pipeline; and support the follow-on clinical trials
needed to assure the safety, immunogenicity, efficacy and
acceptability of new HIV prevention products.
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